1
|
Dopeso-Reyes IG, Wolff M, Andrews MR, Kremer EJ. Editorial: Tropism, Mapping, Modeling, or Therapy Using Canine Adenovirus Type 2 ( CAV-2) Vectors in the CNS. Front Mol Neurosci 2021; 14:636476. [PMID: 33642993 PMCID: PMC7904869 DOI: 10.3389/fnmol.2021.636476] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Accepted: 01/05/2021] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - Mathieu Wolff
- Unité Mixte de Recherche 5287, Centre National de la Recherche Scientifique, INCIA, Université de Bordeaux, Bordeaux, France
| | - Melissa R Andrews
- School of Biological Sciences, University of Southampton, Southampton, United Kingdom
| | - Eric J Kremer
- Institut de Génétique Moléculaire de Montpellier, Université de Montpellier, CNRS, Montpellier, France
| |
Collapse
|
2
|
Bergmann M, Holzheu M, Zablotski Y, Speck S, Truyen U, Hartmann K. Evaluation of a Point-of-Care Test for Pre-Vaccination Testing to Detect Antibodies against Canine Adenoviruses in Dogs. Viruses 2021; 13:v13020183. [PMID: 33530411 PMCID: PMC7911502 DOI: 10.3390/v13020183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 01/19/2021] [Accepted: 01/20/2021] [Indexed: 11/16/2022] Open
Abstract
(1) Background: Antibody testing is commonly used to assess a dog's immune status. For detection of antibodies against canine adenoviruses (CAVs), one point-of-care (POC) test is available. This study assessed the POC test´s performance. (2) Methods: Sera of 198 privately owned dogs and 40 specific pathogen-free (SPF) dogs were included. The reference standard for detection of anti-CAV antibodies was virus neutralization (VN) using CAV-1 and CAV-2 antigens. Specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy (OA) of the POC test were assessed. Specificity was considered most important. (3) Results: Prevalence of CAV-1 neutralizing antibodies (≥10) was 76% (182/238) in all dogs, 92% (182/198) in the subgroup of privately owned dogs, and 0% (0/40) in SPF dogs. Prevalence of CAV-2 neutralizing antibodies (≥10) was 76% (181/238) in all dogs, 91% (181/198) in privately owned dogs, and 0% (0/40) in SPF dogs. Specificity for detection of CAV-1 antibodies was lower (overall dogs, 88%; privately owned dogs, 56%; SPF dogs, 100%) compared with specificity for detection of CAV-2 antibodies (overall dogs, 90%; privately owned dogs, 65%; SPF dogs, 100%). (4) Conclusions: Since false positive results will lead to potentially unprotected dogs not being vaccinated, specificity should be improved to reliably detect anti-CAV antibodies that prevent infectious canine hepatitis in dogs.
Collapse
Affiliation(s)
- Michèle Bergmann
- Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany; (Y.Z.); (K.H.)
- Correspondence: ; Tel.: +49-89-2180-2651
| | - Mike Holzheu
- Clinic of Small Animal Surgery and Reproduction, Centre for Clinical Veterinary Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany;
| | - Yury Zablotski
- Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany; (Y.Z.); (K.H.)
| | - Stephanie Speck
- Institute of Animal Hygiene and Veterinary Public Health, University of Leipzig, An den Tierkliniken 1, 04103 Leipzig, Germany; (S.S.); (U.T.)
| | - Uwe Truyen
- Institute of Animal Hygiene and Veterinary Public Health, University of Leipzig, An den Tierkliniken 1, 04103 Leipzig, Germany; (S.S.); (U.T.)
| | - Katrin Hartmann
- Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany; (Y.Z.); (K.H.)
| |
Collapse
|
3
|
Cerpa JC, Marchand AR, Salafranque Y, Pape JR, Kremer EJ, Coutureau E. Targeting Catecholaminergic Systems in Transgenic Rats With a CAV-2 Vector Harboring a Cre-Dependent DREADD Cassette. Front Mol Neurosci 2020; 13:121. [PMID: 32719584 PMCID: PMC7347982 DOI: 10.3389/fnmol.2020.00121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Accepted: 06/10/2020] [Indexed: 11/13/2022] Open
Abstract
Techniques that allow the manipulation of specific neural circuits have greatly increased in the past few years. DREADDs (Designer receptors exclusively activated by designer drugs) provide an elegant way to manipulate individual brain structures and/or neural circuits, including neuromodulatory pathways. Considerable efforts have been made to increase cell-type specificity of DREADD expression while decreasing possible limitations due to multiple viral vectors injections. In line with this, a retrograde canine adenovirus type 2 (CAV-2) vector carrying a Cre-dependent DREADD cassette has been recently developed. In combination with Cre-driver transgenic animals, the vector allows one to target neuromodulatory pathways with cell-type specificity. In the present study, we specifically targeted catecholaminergic pathways by injecting the vector in knock-in rat line containing Cre recombinase cassette under the control of the tyrosine hydroxylase promoter. We assessed the efficacy of infection of the nigrostriatal pathway and the catecholaminergic pathways ascending to the orbitofrontal cortex (OFC) and found cell-type-specific DREADD expression.
Collapse
Affiliation(s)
- Juan-Carlos Cerpa
- CNRS, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Bordeaux, France.,Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Université de Bordeaux, Bordeaux, France
| | - Alain R Marchand
- CNRS, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Bordeaux, France.,Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Université de Bordeaux, Bordeaux, France
| | - Yoan Salafranque
- CNRS, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Bordeaux, France.,Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Université de Bordeaux, Bordeaux, France
| | - Jean-Rémi Pape
- CNRS, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Bordeaux, France.,Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Université de Bordeaux, Bordeaux, France
| | - Eric J Kremer
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
| | - Etienne Coutureau
- CNRS, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Bordeaux, France.,Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Université de Bordeaux, Bordeaux, France
| |
Collapse
|
4
|
Ramidi A, Ganji VK, Buddala B, Yella NR, Manthani GP, Putty K. E3 Gene-Based Genetic Characterization of Canine Adenovirus-2 Isolated from Cases of Canine Gastroenteritis in India Revealed a Novel Group of the Virus. Intervirology 2020; 62:216-221. [PMID: 32259812 DOI: 10.1159/000507329] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Accepted: 03/17/2020] [Indexed: 11/19/2022] Open
Abstract
Canine adenovirus (CAV) circulates as two distinct serotypes, CAV-1 and CAV-2, which are antigenically related but differ in their clinical manifestations. CAV is one of the important viral agents in the etiology of canine gastroenteritis. Here, we report the molecular surveillance and genetic characterization of CAV from clinical cases of canine gastroenteritis. A total of 302 fecal/rectal swabs were collected from dogs presented with gastroenteritis at various clinics in and around Hyderabad, India during 2018-19. These samples were tested for CAV using polymerase chain reaction with primers designed for the CAV E3 gene and the virus was isolated from positive samples. CAV-2 nucleic acid was present in 4.9% of the test samples. The partial sequence analyses of the E3 gene of the CAV-2 isolates revealed a frameshift mutation by insertion of nucleotide "G" at 1077 position of E3 gene, which resulted in an extension of the polypeptide chain by eleven amino acids. As a result, isolates from the current study formed a novel group, and the virus that was previously subdivided into two groups worldwide is now categorized under three. The study identifies a novel group of CAV-2 circulating in India providing an updated information regarding CAV-2.
Collapse
Affiliation(s)
- Ashwini Ramidi
- Departments of Veterinary Microbiology and Veterinary Biotechnology, College of Veterinary Science, PVNRTVU, Hyderabad, India
| | - Vishweshwar Kumar Ganji
- Departments of Veterinary Microbiology and Veterinary Biotechnology, College of Veterinary Science, PVNRTVU, Hyderabad, India
| | - Bhagyalakshmi Buddala
- Departments of Veterinary Microbiology and Veterinary Biotechnology, College of Veterinary Science, PVNRTVU, Hyderabad, India
| | - Narasimha Reddy Yella
- Departments of Veterinary Microbiology and Veterinary Biotechnology, College of Veterinary Science, PVNRTVU, Hyderabad, India
| | - Gnana Prakash Manthani
- Department of Animal Genetics and Breeding, College of Veterinary Science, PVNRTVU, Hyderabad, India
| | - Kalyani Putty
- Departments of Veterinary Microbiology and Veterinary Biotechnology, College of Veterinary Science, PVNRTVU, Hyderabad, India,
| |
Collapse
|
5
|
di Caudo C, Martínez-Valbuena I, Mundiñano IC, Gennetier A, Hernandez M, Carmona-Abellan M, Marcilla Garcia I, Kremer EJ, Luquin R. CAV-2-Mediated GFP and LRRK2 G2019S Expression in the Macaca fascicularis Brain. Front Mol Neurosci 2020; 13:49. [PMID: 32269512 PMCID: PMC7109318 DOI: 10.3389/fnmol.2020.00049] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 03/09/2020] [Indexed: 12/30/2022] Open
Abstract
Parkinson’s disease is characterized by motor and nonmotor symptoms that gradually appear as a consequence of the selective loss of dopaminergic neurons in the substantia nigra pars compacta. Currently, no treatment can slow Parkinson’s disease progression. Inasmuch, there is a need to develop animal models that can be used to understand the pathophysiological mechanisms underlying dopaminergic neuron death. The initial goal of this study was to determine if canine adenovirus type 2 (CAV-2) vectors are effective gene transfer tools in the monkey brain. A second objective was to explore the possibility of developing a large nonhuman primate that expresses one of the most common genetic mutations causing Parkinson’s disease. Our studies demonstrate the neuronal tropism, retrograde transport, biodistribution, and efficacy of CAV-2 vectors expressing GFP and leucine-rich repeat kinase 2 (LRRK2G2019S) in the Macaca fascicularis brain. Our data also suggest that following optimization CAV-2-mediated LRRK2G2019S expression could help us model the neurodegenerative processes of this genetic subtype of Parkinson’s disease in monkeys.
Collapse
Affiliation(s)
- Carla di Caudo
- Division of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.,Department of Neurology, Clinica Universidad de Navarra, Pamplona, Spain
| | - Ivan Martínez-Valbuena
- Division of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.,Department of Neurology, Clinica Universidad de Navarra, Pamplona, Spain.,Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
| | - Iñaki-Carril Mundiñano
- Division of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain
| | - Aurelie Gennetier
- Institut de Génétique Moléculaire de Montpellier, Université de Montpellier, CNRS, Montpellier, France
| | - Maria Hernandez
- Division of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.,Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
| | - Mar Carmona-Abellan
- Division of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.,Department of Neurology, Clinica Universidad de Navarra, Pamplona, Spain
| | - Irene Marcilla Garcia
- Division of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain
| | - Eric J Kremer
- Institut de Génétique Moléculaire de Montpellier, Université de Montpellier, CNRS, Montpellier, France
| | - Rosario Luquin
- Division of Neuroscience, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.,Department of Neurology, Clinica Universidad de Navarra, Pamplona, Spain.,Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
| |
Collapse
|
6
|
Li SJ, Vaughan A, Sturgill JF, Kepecs A. A Viral Receptor Complementation Strategy to Overcome CAV-2 Tropism for Efficient Retrograde Targeting of Neurons. Neuron 2019; 98:905-917.e5. [PMID: 29879392 DOI: 10.1016/j.neuron.2018.05.028] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Revised: 03/30/2018] [Accepted: 05/17/2018] [Indexed: 12/25/2022]
Abstract
Retrogradely transported neurotropic viruses enable genetic access to neurons based on their long-range projections and have become indispensable tools for linking neural connectivity with function. A major limitation of viral techniques is that they rely on cell-type-specific molecules for uptake and transport. Consequently, viruses fail to infect variable subsets of neurons depending on the complement of surface receptors expressed (viral tropism). We report a receptor complementation strategy to overcome this by potentiating neurons for the infection of the virus of interest-in this case, canine adenovirus type-2 (CAV-2). We designed AAV vectors for expressing the coxsackievirus and adenovirus receptor (CAR) throughout candidate projection neurons. CAR expression greatly increased retrograde-labeling rates, which we demonstrate for several long-range projections, including some resistant to other retrograde-labeling techniques. Our results demonstrate a receptor complementation strategy to abrogate endogenous viral tropism and thereby facilitate efficient retrograde targeting for functional analysis of neural circuits.
Collapse
Affiliation(s)
- Shu-Jing Li
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
| | | | | | - Adam Kepecs
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
| |
Collapse
|
7
|
del Rio D, Beucher B, Lavigne M, Wehbi A, Gonzalez Dopeso-Reyes I, Saggio I, Kremer EJ. CAV-2 Vector Development and Gene Transfer in the Central and Peripheral Nervous Systems. Front Mol Neurosci 2019; 12:71. [PMID: 30983967 PMCID: PMC6449469 DOI: 10.3389/fnmol.2019.00071] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Accepted: 03/07/2019] [Indexed: 12/11/2022] Open
Abstract
The options available for genetic modification of cells of the central nervous system (CNS) have greatly increased in the last decade. The current panoply of viral and nonviral vectors provides multifunctional platforms to deliver expression cassettes to many structures and nuclei. These cassettes can replace defective genes, modify a given pathway perturbed by diseases, or express proteins that can be selectively activated by drugs or light to extinguish or excite neurons. This review focuses on the use of canine adenovirus type 2 (CAV-2) vectors for gene transfer to neurons in the brain, spinal cord, and peripheral nervous system. We discuss (1) recent advances in vector production, (2) why CAV-2 vectors preferentially transduce neurons, (3) the mechanism underlying their widespread distribution via retrograde axonal transport, (4) how CAV-2 vectors have been used to address structure/function, and (5) their therapeutic applications.
Collapse
Affiliation(s)
- Danila del Rio
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
| | - Bertrand Beucher
- PVM, BioCampus, CNRS, INSERM, University of Montpellier, Montpellier, France
| | - Marina Lavigne
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
| | - Amani Wehbi
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
| | | | - Isabella Saggio
- Department of Biology and Biotechnology “C. Darwin”, Sapienza University of Rome, Rome, Italy
- Institute of Structural Biology, School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
| | - Eric J. Kremer
- Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
| |
Collapse
|
8
|
Bru T, Salinas S, Kremer EJ. An update on canine adenovirus type 2 and its vectors. Viruses 2010; 2:2134-2153. [PMID: 21994722 PMCID: PMC3185752 DOI: 10.3390/v2092134] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2010] [Revised: 09/23/2010] [Accepted: 09/24/2010] [Indexed: 12/27/2022] Open
Abstract
Adenovirus vectors have significant potential for long- or short-term gene transfer. Preclinical and clinical studies using human derived adenoviruses (HAd) have demonstrated the feasibility of flexible hybrid vector designs, robust expression and induction of protective immunity. However, clinical use of HAd vectors can, under some conditions, be limited by pre-existing vector immunity. Pre-existing humoral and cellular anti-capsid immunity limits the efficacy and duration of transgene expression and is poorly circumvented by injections of larger doses and immuno-suppressing drugs. This review updates canine adenovirus serotype 2 (CAV-2, also known as CAdV-2) biology and gives an overview of the generation of early region 1 (E1)-deleted to helper-dependent (HD) CAV-2 vectors. We also summarize the essential characteristics concerning their interaction with the anti-HAd memory immune responses in humans, the preferential transduction of neurons, and its high level of retrograde axonal transport in the central and peripheral nervous system. CAV-2 vectors are particularly interesting tools to study the pathophysiology and potential treatment of neurodegenerative diseases, as anti-tumoral and anti-viral vaccines, tracer of synaptic junctions, oncolytic virus and as a platform to generate chimeric vectors.
Collapse
Affiliation(s)
- Thierry Bru
- Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, 1919 Route de Mende Montpellier, 34293 France; E-Mails: (T.B.); (S.S.)
- Université de Montpellier I, 5 Bd Henri IV, 34000 Montpellier, France
- Université de Montpellier II, place Eugène Bataillon, 34090 Montpellier, France
| | - Sara Salinas
- Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, 1919 Route de Mende Montpellier, 34293 France; E-Mails: (T.B.); (S.S.)
- Université de Montpellier I, 5 Bd Henri IV, 34000 Montpellier, France
- Université de Montpellier II, place Eugène Bataillon, 34090 Montpellier, France
| | - Eric J. Kremer
- Institut de Génétique Moléculaire de Montpellier, CNRS UMR 5535, 1919 Route de Mende Montpellier, 34293 France; E-Mails: (T.B.); (S.S.)
- Université de Montpellier I, 5 Bd Henri IV, 34000 Montpellier, France
- Université de Montpellier II, place Eugène Bataillon, 34090 Montpellier, France
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +33-467-613-372; Fax: +33-467-040-231
| |
Collapse
|